MannKind (MNKD) to Release Earnings on Thursday

MannKind (NASDAQ:MNKDGet Rating) is set to issue its quarterly earnings data after the market closes on Thursday, May 5th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

MannKind (NASDAQ:MNKDGet Rating) last released its quarterly earnings data on Thursday, February 24th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The business had revenue of $12.52 million for the quarter, compared to the consensus estimate of $16.99 million. During the same period last year, the business posted ($0.06) earnings per share. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind stock opened at $3.23 on Friday. The firm has a 50-day moving average of $3.46 and a two-hundred day moving average of $4.03. MannKind has a 1 year low of $2.49 and a 1 year high of $5.53. The stock has a market cap of $814.78 million, a price-to-earnings ratio of -10.09 and a beta of 1.98.

Several brokerages have recently weighed in on MNKD. Zacks Investment Research cut shares of MannKind from a “hold” rating to a “sell” rating in a research report on Wednesday. StockNews.com raised shares of MannKind to a “sell” rating in a research report on Thursday, March 24th. Finally, HC Wainwright lowered their price target on shares of MannKind from $6.50 to $6.00 and set a “buy” rating for the company in a research report on Monday, February 28th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, MannKind presently has an average rating of “Hold” and an average target price of $5.50.

In related news, insider Alejandro Galindo purchased 36,900 shares of the business’s stock in a transaction on Monday, February 28th. The shares were acquired at an average price of $2.71 per share, for a total transaction of $99,999.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Anthony C. Hooper purchased 40,000 shares of the business’s stock in a transaction on Monday, February 28th. The shares were bought at an average price of $2.71 per share, for a total transaction of $108,400.00. The disclosure for this purchase can be found here. Insiders have purchased 79,945 shares of company stock valued at $218,052 in the last three months. 2.30% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the company. Paradigm Financial Partners LLC acquired a new stake in shares of MannKind in the fourth quarter worth $43,000. Integrated Wealth Concepts LLC increased its stake in shares of MannKind by 20.5% in the fourth quarter. Integrated Wealth Concepts LLC now owns 14,705 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 2,500 shares during the period. Virtu Financial LLC increased its stake in shares of MannKind by 57.6% in the fourth quarter. Virtu Financial LLC now owns 18,180 shares of the biopharmaceutical company’s stock worth $79,000 after acquiring an additional 6,648 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of MannKind in the third quarter worth $104,000. Finally, Cubist Systematic Strategies LLC increased its stake in shares of MannKind by 102.8% in the third quarter. Cubist Systematic Strategies LLC now owns 53,810 shares of the biopharmaceutical company’s stock worth $234,000 after acquiring an additional 27,271 shares during the period. Hedge funds and other institutional investors own 43.41% of the company’s stock.

MannKind Company Profile (Get Rating)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.

Further Reading

Earnings History for MannKind (NASDAQ:MNKD)

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.